secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2024-09-27T23:59:59+00:00
Accession:  0001193125-24-227950
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CFO Julie Feder to depart Oct 25; VP Finance Amy Elazzouzi named interim CFO
----------------------------------------------------------------------------

- CFO Julie Feder will resign effective Oct 25, 2024; no dispute or disagreement with company.
- Feder will provide consulting services through Dec 31, 2024, and receive severance of 10 months base salary.
- Amy Elazzouzi, VP Finance, appointed interim principal financial and accounting officer effective Oct 25.
- Elazzouzi's annual base salary increased to $360,000; eligible for 30% target bonus.
- Company will search for a permanent CFO during the interim period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312524227950/0001193125-24-227950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312524227950/d707178d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-227950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer